Migraine Drugs– our new study reveals trends, R&D progress, and predicted revenues
Where is the Migraine Drugs market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 234-page report provides 34 tables, 85 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Migraine Drugs market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
– You find original analyses, with business outlooks and developments.
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 3 segmentations of the Migraine Drugs Market, with forecasts for 6 Product Types, 3 Route of Administrations, 3 Distribution Channels, each forecasted at a global and regional level.
Global Migraine Drugs Market by Product Type
– Acute Migraine Treatment
– Analgesic
– Ergotamine
– Triptans
– Preventive Migraine Treatment
– Anti-Convulsants
– Antidepressants
– Anti-Serotonergic Drugs
– Beta Blockers
– Calcium Channel Blockers
– Others
Global Migraine Drugs Market by Route of Administration
– Oral
– Injection
– Others
Global Migraine Drugs Market by Distribution Channel
– Hospital Pharmacies
– Retail Pharmacies
– Online
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets:
– North America:
– US
– Canada
– Latin America:
– Brazil
– Mexico
– Rest of Latin America
– Western Europe:
– Germany
– The UK
– Italy
– France
– Spain
– Nordic
– Benelux
– Rest of Western Europe
– Eastern Europe:
– Russia
– Poland
– Rest of Eastern Europe
– Asia-Pacific:
– Japan
– China
– India
– Australia & New Zealand
– ASEAN
– Rest of Asia-Pacific
– MEA:
– GCC Countries
– South Africa
– Northern Africa
– Rest of MEA
The report also includes profiles and for some of the leading companies in the Migraine Drugs Market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Russia, Germany and China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth
Overall world revenue for Migraine Drugs will surpass $2 bn in 2020, our work calculates. We predict strong revenue growth through to 2030.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Migraine Drugs Market report helps you
In summary, our 234-page report provides you with the following knowledge:
– Revenue forecasts to 2030 for 3 segmentations of the Migraine Drugs Market, with forecasts for 6 Product Types, 3 Route of Administrations, 3 Distribution Channels, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
– Revenue forecasts to 2030 for 6 regional and 21 key national markets – See forecasts for the Migraine Drugs market in North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, the UK, Italy, France, Nordic Countries, Benelux, China, India, Japan, Australia & New Zealand, ASEAN countries, GCC Countries, South Africa and Northern Africa.
– Stimulates and restrains companies and the market
– Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Migraine Drugs market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the migraine drugs market and leading companies. You will find data, trends and predictions.
Get our report today The Migraine Drugs Market Forecast 2020-2030: Revenue Prospects by Product Type (Acute Migraine Treatment, Preventive Migraine Treatment), Route of Administration (Oral, Injection, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), and Geography.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Migraine Drugs Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Global Migraine Drugs Market Size and Forecast
2.3. Market Dynamics
2.3.1. Market Drivers
2.3.1.1. Rise in Awareness Among Patients Towards Migraine Treatment & Prevention
2.3.1.2. Increase in Prevalence of Migraine
2.3.1.3. Development of Novel Therapies
2.3.1.4. Rising Health Expenditure
2.3.2. Market Restraints
2.3.2.1. Side Effects of Migraine Drugs
2.3.3. Global Migraine Drugs Market: Trends
2.3.4. Mergers and Acquisitions
2.3.5. Entry of New Market Players
3. Global Migraine Drugs Market Analysis and Forecast, By Product Type
3.1. Introduction
3.1.1. Global Migraine Drugs Market, Annual Growth Rate Comparison, By Product Type
3.2. Global Migraine Drugs Market Size and Forecast, By Product Type
3.2.1. Acute Migraine Treatment
3.2.1.1. Analgesic
3.2.1.2. Ergotamine
3.2.1.3. Triptans
3.2.2. Preventive Migraine Treatment
3.2.2.1. Anti-Convulsants
3.2.2.2. Antidepressants
3.2.2.3. Anti-Serotonergic Drugs
3.2.2.4. Beta Blockers
3.2.2.5. Calcium Channel Blockers
3.2.2.6. Others
3.3. Global Migraine Drugs Attractiveness Index, By Product Type
4. Global Migraine Drugs Market Analysis and Forecast, By Route of Administration
4.1. Introduction
4.1.1. Global Migraine Drugs Market, Annual Growth Rate Comparison, By Route of Administration
4.1.2. Global Migraine Drugs Market Share Comparison, By Route of Administration (2018 & 2030)
4.2. Global Migraine Drugs Market Size and Forecast, By Route of Administration
4.2.1. Oral
4.2.2. Injection
4.2.3. Others
4.3. Global Migraine Drugs Attractiveness Index, By Route of Administration
5. Global Migraine Drugs Market Analysis and Forecast, By Distribution Channel
5.1. Introduction
5.1.1. Global Migraine Drugs Market, Annual Growth Rate Comparison, By Distribution Channel
5.1.2. Global Migraine Drugs Market Share Comparison, By Distribution Channel (2018 & 2030)
5.2. Global Migraine Drugs Market Size and Forecast, By Distribution Channel
5.2.1. Hospital Pharmacies
5.2.2. Retail Pharmacies
5.2.3. Online
5.3. Global Migraine Drugs Attractiveness Index, By Distribution Channel
6. Global Migraine Drugs Market Analysis and Forecast, By Region
6.1. Introduction
6.1.1. Global Migraine Drugs Market, Annual Growth Rate Comparison, By Region
6.1.2. Global Migraine Drugs Market Share Comparison, By Region (2018 & 2030)
6.2. Global Migraine Drugs Market Size and Forecast, By Region
6.2.1. North America (U.S., Canada)
6.2.2. Latin America (Brazil, Mexico, Rest of Latin America)
6.2.3. Western Europe (UK, France, Germany, Italy, Spain, Nordic, Benelux, RoWE)
6.2.4. Eastern Europe (Russia, Poland, Rest of Eastern Europe)
6.2.5. Asia Pacific (Japan, China, India, ASEAN, Australia, RoAPAC)
6.2.6. MEA (GCC, South Africa, North Africa, RoMEA)
6.3. Global Migraine Drugs Market Attractiveness Index, By Region
7. North America Migraine Drugs Market Analysis and Forecast, 2020-2030
7.1. Introduction
7.1.1. North America Migraine Drugs Market
7.1.2. North America Migraine Drugs Market, Annual Growth Rate Comparison, By Country
7.2. North America Migraine Drugs Market Size and Forecast, By Country
7.2.1. The U.S. Migraine Drugs Market
7.2.2. Canada Migraine Drugs Market
7.3. North America Migraine Drugs Market Size and Forecast, By Product Type
7.4. North America Migraine Drugs Market Size and Forecast, By Route of Administration
7.5. North America Migraine Drugs Market Size and Forecast, By Distribution Channel
7.6. North America Migraine Drugs Market Attractiveness Index
7.7. North America Migraine Drugs Market Attractiveness Index, By Country
7.8. North America Migraine Drugs Market Attractiveness Index, By Product Type
7.9. North America Migraine Drugs Market Attractiveness Index, By Route of Administration
7.10. North America Migraine Drugs Market Attractiveness Index, By Distribution Channel
8. Latin America Migraine Drugs Market Analysis and Forecast, 2020-2030
8.1. Introduction
8.1.1. Latin America Migraine Drugs Market
8.1.2. Latin America Migraine Drugs Market, Annual Growth Rate Comparison, By Country
8.2. Latin America Migraine Drugs Market Size and Forecast, By Country
8.2.1. Brazil Migraine Drugs Market
8.2.2. Mexico Migraine Drugs Market
8.2.3. Rest of Latin America Migraine Drugs Market
8.3. Latin America Migraine Drugs Market Size and Forecast, By Product Type
8.4. Latin America Migraine Drugs Market Size and Forecast, By Route of Administration
8.5. Latin America Migraine Drugs Market Size and Forecast, By Distribution Channel
8.6. Latin America Migraine Drugs Market Attractiveness Index
8.7. Latin America Migraine Drugs Market Attractiveness Index, By Country
8.8. Latin America Migraine Drugs Market Attractiveness Index, By Product Type
8.9. Latin America Migraine Drugs Market Attractiveness Index, By Route of Administration
8.10. Latin America Migraine Drugs Market Attractiveness Index, By Distribution Channel
9. Western Europe Migraine Drugs Market Analysis and Forecast, 2020-2030
9.1. Introduction
9.1.1. Western Europe Migraine Drugs Market
9.1.2. Western Europe Migraine Drugs Market, Annual Growth Rate Comparison, By Country
9.2. Western Europe Migraine Drugs Market Size and Forecast, By Country
9.2.1. U.K. Migraine Drugs Market
9.2.2. France Migraine Drugs Market
9.2.3. Germany Migraine Drugs Market
9.2.4. Italy Migraine Drugs Market
9.2.5. Spain Migraine Drugs Market
9.2.6. Nordic Migraine Drugs Market
9.2.7. Benelux Migraine Drugs Market
9.2.8. Rest of Western Europe Migraine Drugs Market
9.3. Western Europe Migraine Drugs Market Size and Forecast, By Product Type
9.4. Western Europe Migraine Drugs Market Size and Forecast, By Route of Administration
9.5. Western Europe Migraine Drugs Market Size and Forecast, By Distribution Channel
9.6. Western Europe Migraine Drugs Market Attractiveness Index
9.7. Western Europe Migraine Drugs Market Attractiveness Index, By Country
9.8. Western Europe Migraine Drugs Market Attractiveness Index, By Product Type
9.9. Western Europe Migraine Drugs Market Attractiveness Index, By Route of Administration
9.10. Western Europe Migraine Drugs Market Attractiveness Index, By Distribution Channel
10. Eastern Europe Migraine Drugs Market Analysis and Forecast, 2020-2030
10.1. Introduction
10.1.1. Eastern Europe Migraine Drugs Market
10.1.2. Eastern Europe Migraine Drugs Market, Annual Growth Rate Comparison, By Country
10.2. Eastern Europe Migraine Drugs Market Size and Forecast, By Country
10.2.1. Russia Migraine Drugs Market
10.2.2. Poland Migraine Drugs Market
10.2.3. Rest of Eastern Europe Migraine Drugs Market
10.3. Eastern Europe Migraine Drugs Market Size and Forecast, By Product Type
10.4. Eastern Europe Migraine Drugs Market Size and Forecast, By Route of Administration
10.5. Eastern Europe Migraine Drugs Market Size and Forecast, By Distribution Channel
10.6. Eastern Europe Migraine Drugs Market Attractiveness Index
10.7. Eastern Europe Migraine Drugs Market Attractiveness Index, By Country
10.8. Eastern Europe Migraine Drugs Market Attractiveness Index, By Product Type
10.9. Eastern Europe Migraine Drugs Market Attractiveness Index, By Route of Administration
10.10. Eastern Europe Migraine Drugs Market Attractiveness Index, By Distribution Channel
11. Asia Pacific Migraine Drugs Market Analysis and Forecast, 2020-2030
11.1. Introduction
11.1.1. Asia Pacific Migraine Drugs Market
11.1.2. Asia Pacific Migraine Drugs Market, Annual Growth Rate Comparison, By Country
11.2. Asia Pacific Migraine Drugs Market Size and Forecast, By Country
11.2.1. China Migraine Drugs Market
11.2.2. India Migraine Drugs Market
11.2.3. Australia Migraine Drugs Market
11.2.4. ASEAN Migraine Drugs Market
11.2.5. Japan Migraine Drugs Market
11.2.6. Rest of Asia Pacific Migraine Drugs Market
11.3. Asia Pacific Migraine Drugs Market Size and Forecast, By Product Type
11.4. Asia Pacific Migraine Drugs Market Size and Forecast, By Route of Administration
11.5. Asia Pacific Migraine Drugs Market Size and Forecast, By Distribution Channel
11.6. Asia Pacific Migraine Drugs Market Attractiveness Index
11.7. Asia Pacific Migraine Drugs Market Attractiveness Index, By Country
11.8. Asia Pacific Migraine Drugs Market Attractiveness Index, By Product Type
11.9. Asia Pacific Migraine Drugs Market Attractiveness Index, By Route of Administration
11.10. Asia Pacific Migraine Drugs Market Attractiveness Index, By Distribution Channel
12. MEA Migraine Drugs Market Analysis and Forecast, 2020-2030
12.1. Introduction
12.1.1. MEA Migraine Drugs Market
12.1.2. MEA Migraine Drugs Market, Annual Growth Rate Comparison, By Country
12.2. MEA Migraine Drugs Market Size and Forecast, By Country
12.2.1. GCC Migraine Drugs Market
12.2.2. South Africa Migraine Drugs Market
12.2.3. North Africa Migraine Drugs Market
12.2.4. Rest of MEA Migraine Drugs Market
12.3. MEA Migraine Drugs Market Size and Forecast, By Product Type
12.4. MEA Migraine Drugs Market Size and Forecast, By Route of Administration
12.5. MEA Migraine Drugs Market Size and Forecast, By Distribution Channel
12.6. MEA Migraine Drugs Market Attractiveness Index
12.7. MEA Migraine Drugs Market Attractiveness Index, By Country
12.8. MEA Migraine Drugs Market Attractiveness Index, By Product Type
12.9. MEA Migraine Drugs Market Attractiveness Index, By Route of Administration
12.10. MEA Migraine Drugs Market Attractiveness Index, By Distribution Channel
13. Leading Companies in the Migraine Drugs Market
13.1. Competition Dashboard
13.2. Company Share Analysis
13.3. Company Profiling of 15 Major Players
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance (2016-2018)
13.3.4. Recent Initiatives
14. Conclusion
15. Glossary
16. List of Figures
Figure1. Research design
Figure2. Market segmentation & scope
Figure3. Value chain analysis
Figure4. Porter’s Five Forces
Figure5. Market driver analysis (Current & Future Impact)
Figure6. Market restraint analysis (Current & Future Impact)
Figure7. Global Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure8. Global Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure9. Global Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure10. Global Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure11. Global Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure12. Global Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure13. Global Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure14. Global Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure15. Global Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure16. Global Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure17. Global Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure18. North America Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure19. North America Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure20. North America Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure21. North America Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure22. North America Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure23. North America Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure24. North America Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure25. North America Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure26. North America Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure27. North America Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure28. North America Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure29. Latin America Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure30. Latin America Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure31. Latin America Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure32. Latin America Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure33. Latin America Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure34. Latin America Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure35. Latin America Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure36. Latin America Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure37. Latin America Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure38. Latin America Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure39. Latin America Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure40. Western Europe Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure41. Western Europe Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure42. Western Europe Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure43. Western Europe Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure44. Western Europe Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure45. Western Europe Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure46. Western Europe Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure47. Western Europe Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure48. Western Europe Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure49. Western Europe Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure50. Western Europe Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure51. Eastern Europe Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure52. Eastern Europe Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure53. Eastern Europe Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure54. Eastern Europe Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure55. Eastern Europe Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure56. Eastern Europe Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure57. Eastern Europe Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure58. Eastern Europe Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure59. Eastern Europe Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure60. Eastern Europe Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure61. Eastern Europe Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure62. APAC Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure63. APAC Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure64. APAC Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure65. APAC Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure66. APAC Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure67. APAC Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure68. APAC Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure69. APAC Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure70. APAC Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure71. APAC Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure72. APAC Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure73. MEA Migraine Drugs Market by Product Type, 2020-2030 (USD million)
Figure74. MEA Migraine Drugs Market for Acute Migraine Treatment, 2020-2030 (USD million)
Figure75. MEA Migraine Drugs Market for Preventive Migraine Treatment, 2020-2030 (USD million)
Figure76. MEA Migraine Drugs Market by Route of Administration, 2020-2030 (USD million)
Figure77. MEA Migraine Drugs Market for Oral, 2020-2030 (USD million)
Figure78. MEA Migraine Drugs Market for Injection, 2020-2030 (USD million)
Figure79. MEA Migraine Drugs Market for Others, 2020-2030 (USD million)
Figure80. MEA Migraine Drugs Market by Distribution Channel, 2020-2030 (USD million)
Figure81. MEA Migraine Drugs Market for Hospital Pharmacies, 2020-2030 (USD million)
Figure82. MEA Migraine Drugs Market for Retail Pharmacies, 2020-2030 (USD million)
Figure83. MEA Migraine Drugs Market for Online, 2020-2030 (USD million)
Figure84. List of Companies
17. List of Tables
Table1. Global Migraine Drugs Market, by Product Type, 2020-2030 (USD million)
Table2. Global Migraine Drugs Market, by Route of Administration, 2020-2030 (USD million)
Table3. Global Migraine Drugs Market, by Distribution Channel, 2020-2030 (USD million)
Table4. North America Migraine Drugs Market, 2020-2030 (USD million)
Table5. U.S. Migraine Drugs Market, 2020-2030 (USD million)
Table6. Canada Migraine Drugs Market, 2020-2030 (USD million)
Table7. Latin America Migraine Drugs Market, 2020-2030 (USD million)
Table8. Brazil Migraine Drugs Market, 2020-2030 (USD million)
Table9. Mexico Migraine Drugs Market, 2020-2030 (USD million)
Table10. Rest of Latin America Migraine Drugs Market, 2020-2030 (USD million)
Table11. Western Europe Migraine Drugs Market, 2020-2030 (USD million)
Table12. UK Migraine Drugs Market, 2020-2030 (USD million)
Table13. France Migraine Drugs Market, 2020-2030 (USD million)
Table14. Germany Migraine Drugs Market, 2020-2030 (USD million)
Table15. Italy Migraine Drugs Market, 2020-2030 (USD million)
Table16. Nordic Migraine Drugs Market, 2020-2030 (USD million)
Table17. Benelux Migraine Drugs Market, 2020-2030 (USD million)
Table18. Rest of Western Europe Migraine Drugs Market, 2020-2030 (USD million)
Table19. Eastern Europe Migraine Drugs Market, 2020-2030 (USD million)
Table20. Russia Migraine Drugs Market, 2020-2030 (USD million)
Table21. Poland Migraine Drugs Market, 2020-2030 (USD million)
Table22. Rest of Eastern Europe Migraine Drugs Market, 2020-2030 (USD million)
Table23. Asia Pacific Migraine Drugs Market, 2020-2030 (USD million)
Table24. Japan Migraine Drugs Market, 2020-2030 (USD million)
Table25. India Migraine Drugs Market, 2020-2030 (USD million)
Table26. Australia Migraine Drugs Market, 2020-2030 (USD million)
Table27. ASEAN Migraine Drugs Market, 2020-2030 (USD million)
Table28. China Migraine Drugs Market, 2020-2030 (USD million)
Table29. Rest of Asia Pacific Migraine Drugs Market, 2020-2030 (USD million)
Table30. MEA Migraine Drugs Market, 2020-2030 (USD million)
Table31. South Africa Migraine Drugs Market, 2020-2030 (USD million)
Table32. North Africa Migraine Drugs Market, 2020-2030 (USD million)
Table33. GCC Migraine Drugs Market, 2020-2030 (USD million)
Table34. Rest of MEA Migraine Drugs Market, 2020-2030 (USD million)
1. Abbott Labrotatories
1.1. Company Overview
1.2. Product Offerings
1.3. Financial Performance (2016-2018)
1.4. Recent Initiatives
2. Aegis Therapeutics, LLC.
2.1. Company Overview
2.2. Product Offerings
2.3. Financial Performance (2016-2018)
2.4. Recent Initiatives
3. Allergan
3.1. Company Overview
3.2. Product Offerings
3.3. Financial Performance (2016-2018)
3.4. Recent Initiatives
4. Amgen
4.1. Company Overview
4.2. Product Offerings
4.3. Financial Performance (2016-2018)
4.4. Recent Initiatives
5. Astrazeneca PLC
5.1. Company Overview
5.2. Product Offerings
5.3. Financial Performance (2016-2018)
5.4. Recent Initiatives
6. Eli Lilly
6.1. Company Overview
6.2. Product Offerings
6.3. Financial Performance (2016-2018)
6.4. Recent Initiatives
7. Endo International Plc.
7.1. Company Overview
7.2. Product Offerings
7.3. Financial Performance (2016-2018)
7.4. Recent Initiatives
8. GlaxoSmithKline Plc.
8.1. Company Overview
8.2. Product Offerings
8.3. Financial Performance (2016-2018)
8.4. Recent Initiatives
9. Impax Laboratories
9.1. Company Overview
9.2. Product Offerings
9.3. Financial Performance (2016-2018)
9.4. Recent Initiatives
10. Johnson & Johnson
10.1. Company Overview
10.2. Product Offerings
10.3. Financial Performance (2016-2018)
10.4. Recent Initiatives
11. Merck & Co.
11.1. Company Overview
11.2. Product Offerings
11.3. Financial Performance (2016-2018)
11.4. Recent Initiatives
12. Novartis International AG
12.1. Company Overview
12.2. Product Offerings
12.3. Financial Performance (2016-2018)
12.4. Recent Initiatives
13. Pfizer
13.1. Company Overview
13.2. Product Offerings
13.3. Financial Performance (2016-2018)
13.4. Recent Initiatives
14. Sanofi SA
14.1. Company Overview
14.2. Product Offerings
14.3. Financial Performance (2016-2018)
14.4. Recent Initiatives
15. Teva Pharmaceutical Industries Limited
15.1. Company Overview
15.2. Product Offerings
15.3. Financial Performance (2016-2018)
15.4. Recent Initiatives